Sinopharm Covid-19 vaccine to be considered for injections on children over 3 years old, Thai FDA reveals

National –

Representatives of the Sinopharm manufacturer in Thailand are proposing permission to distribute the vaccine for children aged over 3 years old, the Food and Drug Administration (FDA) reported today, September 8th.

Dr. Paisarn Dunkum, the Deputy Secretary-General of the FDA, revealed that Biogenie Tech Co., Ltd., an authorized distributor of Sinopharm in Thailand, has requested permission to extend the legitimate age group for Sinopharm use, originally from over 18 years old to over 3 years old.

The FDA committee is now considering the vaccine’s safety and efficacy and will announce the consideration as quickly as possible within 30 days, according to the Deputy Secretary-General.

The Pattaya News/TPN media noted that, currently, there are two vaccines that are allowed in Thailand for people over 12 years old which are Pfizer and Moderna. Sinopharm was the first brand that has been proposed for injection in children over 3 years old.

The hope is that if this was approved it would be a safe way for children to return to school in Thailand.

Meanwhile, the Chulabhorn Royal Academy today, September 8th, 2021, has opened applications for educational institutions to request Sinopharm Covid-19 vaccines for their students without fees, available for 50,000 students in total.

The campaign is to potentially build immunity among students before the start of the new semester. The schedule for the injections in registered schools will be announced from September 20th onwards.


Follow us on Facebook,

Join us on LINE for breaking alerts!


User Review
0 (0 votes)
Nop Meechukhun
National News Writer at The Pattaya News from September 2020 to October 2022. Born and raised in Bangkok, Nop enjoys telling stories of her hometown through her words and pictures. Her educational experience in the United States and her passion for journalism have shaped her genuine interests in society, politics, education, culture, and art.